Browsing Tag
WELIREG
5 posts
Merck’s KEYTRUDA + WELIREG combo shows major disease-free survival benefit in clear cell renal cell carcinoma after surgery
Find out how Merck’s KEYTRUDA + WELIREG combo improved disease-free survival after kidney cancer surgery and what it means for the oncology market.
October 28, 2025
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
October 28, 2025
Merck’s kidney cancer breakthrough hits one target—Will it be enough to change how doctors treat RCC?
Merck and Eisai’s new kidney cancer combination met a key Phase 3 goal. Discover what it means for patients, investors, and the oncology landscape.
October 28, 2025
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment…
December 13, 2024
Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical…
August 20, 2023